Our proprietary neural exosomes inherently cross the blood-brain barrier and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders.


Our preclinical studies have demonstrated the therapeutic potential of our exosomes in multiple stroke models, which has led us to develop a rich, therapeutically diverse pipeline of newly identified disease opportunities.